Winners will be announced on August 23, 2022!
X
Cisco Global Problem Solver Challenge 2022

$1 Million USD in Prizes

Calling All #TechForGood Startups

How can your early-stage innovative technology solution solve the world’s most pressing social and environmental problems?

NurLabs

NurLabs

National Cancer Institute research shows that liquid biopsies (biomarker tests) can complement current standard-of-care screening. Liquid biopsy holds tremendous potential to transform the diagnosis and treatment paradigm for cancer. The first generation of liquid biopsies currently rely on biomarkers found in later stages. In contrast, our platform examines the couriers carrying cargo between cells, a living process in all stages. Cancer cells produce 10x more couriers than normal cells, making this biomarker easier to detect in early-stage cancers. NurLabs is a patent-pending materials science + bioinformatics approach to detect cancer early when it’s most treatable. We bring a fresh perspective to an old problem.